We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
- Authors
Chong Kun Im; Hei-Cheul Jeung; Sun Young Rha; Nae Choon Yoo; Sung Hoon Noh; Jae Kyung Roh; Hyun Cheol Chung
- Abstract
The aim of this study was to investigate the efficacy and safety of the combination chemotherapy of paclitaxel, infusional 5-fluorouracil (5-FU) and leucovorin (FLT regimen) in advanced gastric cancer. The primary end point was the time to progression (TTP). Patients with evaluable disease with or without measurable lesions received 175 mg/m2 paclitaxel on day 1 followed by 20 mg/m2 leucovorin and 24-h infusion of 5-FU 1,000 mg/m2 (day 1-3) repeated every 3 weeks. Sixty patients were enrolled. The median TTP and overall survival duration were 13 and 60 weeks, respectively. One-year survival rate was 53.3%. Of the 50 patients with measurable lesion, the overall response rate was 31.7%. The most common grade 3–4 adverse event was neutropenia (61.7%). The FLT regimen showed an efficacy comparable to other regimens of cisplatin or anthracycline combinations with the advantage of remarkably low non-hematological toxicity. These data about the efficacy of this regimen need confirmation in a phase III trial.
- Subjects
COMBINATION drug therapy; PACLITAXEL; FOLINIC acid; GASTROINTESTINAL cancer; PRECANCEROUS conditions
- Publication
Cancer Chemotherapy & Pharmacology, 2008, Vol 61, Issue 2, p315
- ISSN
0344-5704
- Publication type
Article
- DOI
10.1007/s00280-007-0508-6